Improving survival results after surgical management of malignant pleural mesothelioma: An Australian institution experience

Annals of Thoracic and Cardiovascular Surgery

Volumn 17, Issue 3, 2011, Pages 243-249

  Yan, Tristan D ^a,b   Cao, Christopher Q ^a,b   Boyer, Michael ^a,c   Tin, Mo Mo ^a,c   Kennedy, Catherine ^a,b   Mclean, Jocelyn ^a,b   Bannon, Paul G ^a,b   Mccaughan, Brian C ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b Lung Surgical Research   (Australia)

^c SYDNEY CANCER CENTRE   (Australia)

Author keywords

Decortication; Pleural mesothelioma; Pleurectomy; Pleurodesis and extrapleural pneumonectomy

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; ARTICLE; AUSTRALIA; CHI SQUARE DISTRIBUTION; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; MESOTHELIOMA; MIDDLE AGED; MORTALITY; PLEURA TUMOR; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; THORAX SURGERY; TIME; TREATMENT OUTCOME;

AGED; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MESOTHELIOMA; MIDDLE AGED; NEW SOUTH WALES; PLEURAL NEOPLASMS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; THORACIC SURGICAL PROCEDURES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79959764717     PISSN: 13411098     EISSN: None     Source Type: Journal    
DOI: 10.5761/atcs.oa.10.01572     Document Type: Article

References (25)

1. Robinson BW, Lake RA. Advances in malignantmes othelioma. N Engl J Med 2005; 353: 1591-603.
2. Alberts A, Falkson G, Goedhals L, Vorobiof D, Van der Merwe C. Malignant pleural mesothelioma: a diseaseunaffected by current therapeutic maneuvers. J Clin Oncol 1998; 6: 527-35.
3. Herndon J, Green M, Chahinian A, Corson J, Suzuki Y, et al. Factors predictive of survival among 337 patientswith mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113:723-31.
4. Rusch V. A proposed new international TNM stagingsystem for malignant pleural mesothelioma. From the international mesothelioma interest group. Chest 1995;108: 1122-8.
5. Brancatisano R, Joseph M, McCaughan B. Pleurectomyfor mesothelioma. Med J Aust 1991; 154: 455-60.
6. Martin-Ucar AE, Edwards JG, Rengajaran A, Muller S, Waller DA. Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control. Eur J Cardiothorac Surg 2001; 20: 1117-21.
7. Soysal O, Karaoglanoglu N, Demircan S, Topcu S, Tastepe I, et al. Pleurectomy/decortication for palliationin malignant pleural mesothelioma: results of surgery. Eur J Cardiothorac Surg 1997; 11: 210-3.
8. Merritt N, Blewett CJ, Miller JD, Bennett WF, Young JE, et al. Survival after conservative (palliative) management of pleural malignant mesothelioma. J Surg Oncol 2001; 78: 171-4.
9. Grondin S, Sugarbaker D. Pleuropneumonectomy in the treatment of malignant pleural mesothelioma. Chest 1999; 116: 450-4.
10. de Vries WJ, Long MA. Treatment of mesothelioma inBloemfontein, South Africa. Eur J Cardiothorac Surg 2003; 24: 434-440.
11. Allen K, Faber L, Warren W. Malignant pleural mesothelioma:extrapleural pneumonectomy and pleurectomy. Chest Surg Clin N Am 1994; 4: 113-26.
12. Yajnik S, Rosenzweig KE, Mychalczak B, Krug L, Flores R, et al. Hemithoracic radiation after extra leuralpneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2003; 56: 1319-26.
13. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003 Jul 15; 21: 2636-44.
14. Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, et al. Phase II study of pemetrexed plus carboplatinin malignant pleural mesothelioma. J Clin Oncol 2006; 24: 1443-1448.
15. Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleuralmesothelioma (MPM). Ann Oncol 2008; 19: 370-3.
16. Sugarbaker DJ. Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. J Thorac Oncol 2006; 1: 175-6.
17. Antman K, Shemin R, Ryan L, Klegar K, Osteen R, et al. Malignant mesothelioma: prognostic variables in are gistry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 1988; 6: 147-53.
18. Richards WG, Zellos L, Bueno R, Jaklitsch MT, Janne PA, et al. Phase I to II study of pleurectomy/decorticationand intraoperative intracavitary hyperthermic cisplatinlavage for mesothelioma. J Clin Oncol 2006; 24:1561-7.
19. Rusch V, Saltz L, Venkatraman E, Ginsberg R, McCormack P, et al. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 1994; 12: 1156-63.
20. Ceresoli GL, Locati LD, Ferreri AJ, Cozzarini C, Passoni P, et al. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 2001; 34: 279-87.
21. Chowdhury MM, Dagash H, Pierro A. A systematicreview of the impact of volume of surgery and specializationon patient outcome. Br J Surg 2007; 94:145-61.
22. de Perrot M, McRae K, Anraku M, Karkouti K, Waddell TK, et al. Risk factors for major complications after extra pleural pneumonectomy for malignant pleural mesothelioma. Ann Thorac Surg 2008; 85: 1206-10.
23. Stewart DJ, Martin-Ucar AE, Edwards JG, West K, Waller DA. Extra-pleural pneumonectomy for malignant pleural mesothelioma: the risks of induction chemo therapy, right-sided procedures and prolonged operations. Eur J Cardiothorac Surg 2005; 27: 373-8.
24. Sugarbaker D, Norberto J. Multimodality management of malignant pleural mesothelioma. Chest 1998; 113:61-5.
25. Flores RM, Krug LM, Rosenzweig KE, Venkatraman E, Vincent A, et al. Induction chemotherapy, extra pleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 2006; 1:289-95.